Smiths Detection Inks MDx License with Novartis | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Smiths Detection and Novartis Diagnostics have signed a license and collaboration agreement to develop and commercialize Smiths Detection's Bio-Seeq PCR-based instrument and infectious disease diagnostic tests.

Smiths will develop and enhance the Bio-Seeq platform for use in a range of point-of-care diagnostic tests that Novartis Diagnostics will then move through clinical trials, regulatory affairs, and sales and marketing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.